Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Breast Cancer Patients With Brain Metastases
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Capecitabine
- Indications Breast cancer
- Focus Therapeutic Use
- 19 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 19 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated